HCW Biologics, Inc. HCWB 深 沪
等待开盘 04-01 09:30:00 美东时间
0.36
-0.001
-0.25%
华盛通- 最 高0.3739
- 今 开0.3537
- 成交量 42.32万股
- 最 低 0.3395
- 昨 收 0.3609
- 总市值 207.26万
- 52周最高 17.7999
- 市盈率 静 --
- 换手率 7.35%
- 52周最低 0.3395
- 委 比 -20.00%
- 总股本 575.71万
- 历史最高 311.00
- 量 比 0.53
- 振 幅 9.53%
- 历史最低 0.3395
- 每 手 1
- 风险率 2.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HCW Biologics Q4 EPS $(1.02) Up From $(3.19) YoY, Sales $27.010K Down From $394.804K YoY
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(1.02) per share. This is a 68.03 percent increase over losses of $(3.19) per share from the same period last year. The company reported $27.010 thousand in
今天 05:19
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Firefly Neuroscience (NASDAQ:AIFF) stock rose 25.5% to $1.92 during Fr...
03-21 05:05
HCW Biologics shares are trading higher after the company announced results for HCW9206 production platform for CAR-T cell therapies.
HCW Biologics shares are trading higher after the company announced results for...
03-16 21:27
HCW Biologics Regains Nasdaq Compliance
HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link
03-02 21:14
HCW Biologics, WY Biotech Commence License Agreement To Deploy, Commercialize Rights For Certain In Vivo Applications For HCW11-006
HCW Biologics Inc. ("HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend health span by targeting the link
02-13 21:36
HCW Biologics Begins Phase 1 Trial for HCW9302
The latest update is out from HCW Biologics ( ($HCWB) ). On November 18, 2025, ...
2025-11-18 20:59
HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate of $1.58 by 227.85 percent. This is a 49.5 percent increase over losses of $(4.00) per share from the
2025-11-15 05:47
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
HCW Biologics reported its third-quarter 2025 financial results and business highlights, including the planned Phase 1 clinical trial for HCW9302, a novel immunotherapy targeting autoimmune diseases, and the launch of a search for a commercial partner for its T-cell engager compounds. The company also highlighted the IND-enabling studies for HCW9302 and showcased data for its second-generation TCE and immune checkpoint inhibitor programs. Despite...
2025-11-14 21:44
HCW Biologics Unveils New Cancer Therapy Designed to 'Reawaken' Immune Cells to Fight Solid Tumors
HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting
2025-11-07 20:09
HCW Biologics Granted Nasdaq Compliance Extension
HCW Biologics ( ($HCWB) ) just unveiled an announcement. On August 19, 2025, HC...
2025-10-16 21:30
